202 related articles for article (PubMed ID: 34694893)
1. Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial.
Yazaki Y; Nakamura M; Iijima R; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
Circulation; 2021 Oct; 144(17):1449-1451. PubMed ID: 34694893
[No Abstract] [Full Text] [Related]
2. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R; Miyauchi K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
JAMA Cardiol; 2022 Aug; 7(8):787-794. PubMed ID: 35704345
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.
Matoba T; Yasuda S; Kaikita K; Akao M; Ako J; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
JACC Cardiovasc Interv; 2021 Nov; 14(21):2330-2340. PubMed ID: 34736731
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis.
Ishii M; Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
J Am Heart Assoc; 2022 Nov; 11(21):e027107. PubMed ID: 36285792
[No Abstract] [Full Text] [Related]
7. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Škorňová I; Samoš M; Bolek T; Stančiaková L; Vádelová Ľ; Galajda P; Staško J; Kubisz P; Mokáň M
Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings.
Arashi H; Yamaguchi J; Hagiwara N; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Kimura K; Hirayama A; Matsui K; Ogawa H;
Thromb Haemost; 2022 Sep; 122(9):1584-1593. PubMed ID: 35697255
[TBL] [Abstract][Full Text] [Related]
9. New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial.
Ferreira JP; Cleland JG; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; LaPolice DA; Greenberg B; Zannad F
Clin Res Cardiol; 2022 Jan; 111(1):50-59. PubMed ID: 34128083
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
Am Heart J; 2021 Jun; 236():59-68. PubMed ID: 33657403
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
[TBL] [Abstract][Full Text] [Related]
14. [Large studies of NOAC shows good and safe stroke protection].
Hijazi Z; Oldgren J
Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
[No Abstract] [Full Text] [Related]
15. Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?
Ahmad T; Butler J
Eur J Heart Fail; 2015 Jul; 17(7):647-51. PubMed ID: 26018996
[No Abstract] [Full Text] [Related]
16. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
17. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem.
Bartlett JW; Renner E; Mouland E; Barnes GD; Kuo L; Ha NB
Ann Pharmacother; 2019 Jan; 53(1):21-27. PubMed ID: 30099888
[TBL] [Abstract][Full Text] [Related]
18. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
van Diepen S; Hellkamp AS; Patel MR; Becker RC; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
Circ Heart Fail; 2013 Jul; 6(4):740-7. PubMed ID: 23723250
[TBL] [Abstract][Full Text] [Related]
20. Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Gibson CM; Hankey GJ; Nafee T; Welsh RC
Thromb Haemost; 2018 May; 118(S 01):S34-S44. PubMed ID: 29566416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
